Article
Oncology
Ondrej Fiala, Pavel Ostasov, Aneta Rozsypalova, Milan Hora, Ondrej Sorejs, Jan Sustr, Barbora Bendova, Ivan Travnicek, Jan Filipovsky, Jindrich Finek, Tomas Buchler
Summary: The retrospective study analyzed clinical data from 343 patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib or pazopanib, and found that the use of metformin was associated with significantly longer progression-free survival (PFS) and overall survival (OS) compared to non-users. The Cox multivariate analysis confirmed that metformin use remained a significant factor for both PFS and OS, indicating a favorable outcome for mRCC patients receiving sunitinib or pazopanib treatment.
CANCER MANAGEMENT AND RESEARCH
(2021)
Article
Biochemistry & Molecular Biology
Filipa Amaro, Carolina Pisoeiro, Maria Joao Valente, Maria de Lourdes Bastos, Paula Guedes de Pinho, Marcia Carvalho, Joana Pinto
Summary: This study compared the different cellular and metabolic responses of sunitinib and pazopanib in treating metastatic renal cell carcinoma, suggesting that sunitinib has better in vitro efficacy against target RCC cells and lesser nephrotoxic potential than pazopanib.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Medicine, General & Internal
T. K. Choueiri, T. Powles, M. Burotto, B. Escudier, M. T. Bourlon, B. Zurawski, V. M. Oyervides Juarez, J. J. Hsieh, U. Basso, A. Y. Shah, C. Suarez, A. Hamzaj, J. C. Goh, C. Barrios, M. Richardet, C. Porta, R. Kowalyszyn, J. P. Feregrino, J. Zolnierek, D. Pook, E. R. Kessler, Y. Tomita, R. Mizuno, J. Bedke, J. Zhang, M. A. Maurer, B. Simsek, F. Ejzykowicz, G. M. Schwab, A. B. Apolo, R. J. Motzer
Summary: The study demonstrates that nivolumab plus cabozantinib has significant advantages over sunitinib in the treatment of previously untreated advanced renal-cell carcinoma, including progression-free survival, overall survival, and likelihood of response.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Oncology
Yun Peng, Shiqiang Dong, Yuxuan Song, Dingkun Hou, Lili Wang, Bowen Li, Haitao Wang
Summary: This study identified key immune-related genes and hub genes associated with sunitinib and immune infiltration in clear cell RCC (ccRCC), providing insights into sunitinib resistance and potential biomarkers or drug targets for ccRCC.
Article
Oncology
Predrag Nikic, Nada Babovic, Zoran Dzamic, Svetlana Salma, Vesna Stojanovic, Suzana Matkovic, Zoran Pejcic, Kristina Juskic, Ivan Soldatovic
Summary: This retrospective observational study analyzed data from a nationally representative cohort of 759 patients with mRCC in Serbia who received first-line sunitinib or pazopanib. The results showed modest improvements in overall survival for patients with mRCC in real world clinical practice when only sunitinib and pazopanib were available as first-line treatments.
FRONTIERS IN ONCOLOGY
(2022)
Review
Pharmacology & Pharmacy
Juan Jin, Yuhao Xie, Jin-Shi Zhang, Jing-Quan Wang, Shi-Jie Dai, Wen-fang He, Shou-Ye Li, Charles R. Ashby Jr, Zhe-Sheng Chen, Qiang He
Summary: Renal cell carcinoma (RCC) is the most prevalent type of kidney cancer, and targeted therapy with Sunitinib has become the main treatment option due to the lack of efficacy in radiation therapy and chemotherapy. However, many patients develop resistance to Sunitinib within months of therapy. In this review, we discuss the molecular mechanisms of Sunitinib resistance, strategies to overcome it, and potential predictive biomarkers.
DRUG RESISTANCE UPDATES
(2023)
Article
Oncology
Zeshen Wu, Yulu Peng, Longbin Xiong, Jun Wang, Zhen Li, Kang Ning, Minhua Deng, Ning Wang, Wensu Wei, Zhiyong Li, Pei Dong, Chunping Yu, Fangjian Zhou, Zhiling Zhang
Summary: This study reveals that Sam68 protein impacts the sensitivity to the drug Sunitinib by mediating cell apoptosis. The expression level of Sam68 is higher in Sunitinib-sensitive tumor tissues, and downregulation of Sam68 inhibits Sunitinib-induced cell apoptosis. These findings suggest that Sam68 expression level may serve as a biomarker for predicting Sunitinib sensitivity in RCC patients.
Review
Pharmacology & Pharmacy
Yunxia Wang, Xiaolin Liu, Luyao Gong, Weihong Ding, Wenjing Hao, Yeheng Peng, Jun Zhang, Weimin Cai, Yuan Gao
Summary: This review summarizes the mechanisms of sunitinib resistance in renal cell carcinoma, including activation of bypass or alternative pathways, inadequate drug accumulation, tumor microenvironment, metabolic reprogramming, and epigenetic regulation. It also covers current and potential biomarkers as well as treatment strategies for overcoming sunitinib resistance.
BRITISH JOURNAL OF PHARMACOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Tomonori Sato, Yoshihide Kawasaki, Masamitsu Maekawa, Shinya Takasaki, Kento Morozumi, Masahiko Sato, Shuichi Shimada, Naoki Kawamorita, Shinichi Yamashita, Koji Mitsuzuka, Nariyasu Mano, Akihiro Ito
Summary: Metabolomics analysis can identify potential therapeutic targets for treatment resistance in cancer, such as sunitinib resistance in renal cell carcinoma (RCC), through changes in metabolites. This study found that alterations in energy metabolism, glycolysis upregulation, and antioxidant activity are associated with sunitinib resistance in RCC cells.
Article
Oncology
Cora N. Sternberg, Ian D. Davis, Jozef Mardiak, Cezary Szczylik, Eunsik Lee, John Wagstaff, Carlos H. Barrios, Pamela Salman, Oleg A. Gladkov, Alexander Kavina, Juan J. Zarba, Mei Chen, Lauren McCann, Lini Pandite, Debasish F. Roychowdhury, Robert E. Hawkins
Summary: This study evaluated the efficacy and safety of Pazopanib in the treatment of advanced renal cell carcinoma. The results showed significant improvement in progression-free survival and tumor response with Pazopanib compared to placebo.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Xiaoyi Du, Zhipeng Zhao, Xin Zhao, Hexi Wang, Li Jiang, Wei Tang
Summary: In this study, we analyzed the subtypes of ccRCC mediated by 8 TSGs contained in the 3p21.3 gene cluster and their effects on TME cell infiltration. A risk score model was established to predict prognosis and drug sensitivity. The hub gene NPRL2 was found to promote sunitinib sensitivity in ccRCC cells.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
(2023)
Article
Biochemistry & Molecular Biology
Xin Wang, Jiang-Hua Jia, Ming Zhang, Qing-Song Meng, Bo-Wen Yan, Zi-Yue Ma, Dong-Bin Wang
Summary: This study found that the upregulation of ADM enhanced the chemoresistance of sunitinib by inhibiting FDX1 expression through cuproptosis. Mechanistically, ADM activates the p38/MAPK signaling pathway to promote FOXO3 phosphorylation and its entry into the nucleus, resulting in the inhibition of FDX1 transcription and cell cuproptosis, ultimately promoting chemoresistance in ccRCC.
Article
Andrology
Jianhui Chen, Wen Ye, Wei Jiang, Xiaofan Li, Rong Liu, Bijuan Lin, Jingnan Xiang, Wei Tian, Junjie Bai, Teng Zuo, Bingxin Lin, Yinan Guo, Song Zheng
Summary: The study demonstrated that pazopanib showed efficacy and safety in Chinese patients with mRCC in the real-world setting, especially performing well in the favorable risk subgroup. The most common adverse events reported were change in hair color, diarrhea, and hypertension.
TRANSLATIONAL ANDROLOGY AND UROLOGY
(2021)
Article
Oncology
Kei Nagase, Takashi Akutagawa, Mihoko Rikitake-Yamamoto, Sayuri Morito, Maki Futamata, Shohei Tobu, Mitsuru Noguchi, Shuji Toda, Shigehisa Aoki
Summary: This study investigated the cellular and physical microenvironments of RCC, exploring their regulatory effects on RCC behavior. The results showed that adipose tissue, macrophages, and fluid flow influence the proliferative and invasive capacity of RCC cells, and these effects may be mediated through the extracellular signal-regulated kinase and p38 signaling pathways.
JOURNAL OF PATHOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Qi Wang, Su Gao, Yi Shou, Yujie Jia, Zhihao Wei, Yuenan Liu, Jian Shi, Daojia Miao, Qi Miao, Chuanyi Zhao, Chenchen Liu, Hongmei Yang, Tianbo Xu, Xiaoping Zhang
Summary: In this study, AIM2 was identified as a new biomarker of RCC and promoted RCC progression and sunitinib resistance through FOXO3a-ACSL4 axis-regulated ferroptosis. This finding provides new ideas and therapeutic targets for the diagnosis and treatment of RCC.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
(2023)
Article
Oncology
Chunru Xu, Changwei Yuan, Cuijian Zhang, Dong Fang, Yanfei Yu, Xiang Wang, Zhihua Li, Yan Wang, Qi Tang, Gengyan Xiong, Lei Zhang, Zhisong He, Jian Lin, Liqun Zhou, Xuesong Li
Summary: Over the past 20 years, the clinicopathological diagnostic features of upper tract urothelial carcinoma in the Chinese population have significantly changed, indicating an increased risk of poorer prognosis for UTUC.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Yueming Wang, Jiwei Huang, Cuijian Zhang, Xiaoyi Hu, Ping Wang, Guohai Shi, Jin Zhang, Wen Kong, Yonghui Chen, Yiran Huang, Dingwei Ye, Dan Xia, Jianming Guo, Zhisong He, Wei Xue
Summary: This retrospective multicenter study analyzed the clinical outcomes and prognostic factors of 85 patients who underwent targeted therapy for local retroperitoneal recurrence (RPR) after radical nephrectomy (RN). The study found that presurgical targeted therapy followed by surgical resection was associated with better cancer-specific survival (CSS) compared to targeted therapy alone. Factors such as risk classification, number of recurrence lesions, and surgical resection were independent predictors of CSS.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Article
Green & Sustainable Science & Technology
Botao Jiang, Zhisong He, Wei Xue, Cheng Yang, Hanbo Zhu, Yifei Hua, Bin Lu
Summary: This study used a time-varying difference-in-difference method to examine the effectiveness of the low-carbon city pilot policy in reducing carbon emissions in China. The results show that the policy has a significant impact, especially in cities located in the eastern areas and with high economic development. Furthermore, the policy has a sustainable and lagging effect, leading to greater carbon reductions over time. The study also highlights the mediating effect of electricity consumption in carbon emissions reduction. Overall, the findings contribute to evaluating the achievements of the policy and providing empirical insights for future environmental policymaking.
Article
Oncology
Jiwei Huang, Yueming Wang, Cuijian Zhang, Xiaoyi Hu, Ping Wang, Guohai Shi, Liang Dong, Jin Zhang, Wen Kong, Yonghui Chen, Dan Xia, Jianming Guo, Wei Xue, Yiran Huang, Zhisong He
Summary: Patients who underwent RPR surgery had significantly longer CSS than those who received targeted therapy alone.
CLINICAL GENITOURINARY CANCER
(2023)
Article
Oncology
Xinan Sheng, DingWei Ye, Aiping Zhou, Xin Yao, Hong Luo, Zhisong He, Zengjun Wang, Yingchao Zhao, Zhigang Ji, Qing Zou, Chaohong He, Jianming Guo, Xinhua Tu, Ziling Liu, Benkang Shi, Ben Liu, Peng Chen, Qiang Wei, Zhiquan Hu, Yanqiao Zhang, Kui Jiang, Fangjian Zhou, Dapeng Wu, Cheng Fu, Xingya Li, Bin Wu, Lijie Wang, Shukui Qin, Gang Li, Yunpeng Liu, Hongqian Guo, Kehe Chen, Dahong Zhang, Gongxian Wang, Lieming Ding, Yang Wang, Xiaobin Yuan, Jun Guo
Summary: This study aimed to evaluate the efficacy of vorolanib in combination with everolimus or as monotherapy compared to everolimus alone as second-line treatment for metastatic renal cell carcinoma (RCC). The results showed that the combination of vorolanib and everolimus had a significant improvement in progression-free survival (PFS) and objective response rate compared to everolimus alone. However, there was no significant difference in PFS and objective response rate between vorolanib monotherapy and everolimus. Overall, this study offers a better treatment option for patients with metastatic RCC.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Biochemistry & Molecular Biology
Kaiwei Yang, Hailong Hu, Junlong Wu, Huina Wang, Zhaoxia Guo, Wei Yu, Lin Yao, Feng Ding, Tao Zhou, Wang Wang, Yunkai Wang, Lei Liu, Jing Guo, Shuaipeng Zhu, Xinhao Zhang, Shanbo Cao, Feng Lou, Yuanjie Niu, Dingwei Ye, Zhisong He
Summary: Current methods for early detection and MRD monitoring of urothelial carcinoma (UC) are invasive or suboptimal in sensitivity. A new workflow called utLIFE, based on UC-specific mutations and large copy number variations, can detect UC with high sensitivity and specificity. It has been validated in bladder cancer and upper tract urothelial carcinoma cohorts, showing improved sensitivity compared to cytology and fluorescence in situ hybridization (FISH).
Article
Andrology
Xin Qi, Zhuo-Fei Zhang, Xian-Shu Gao, Shang-Bin Qin, Yun Bai, Wei Yu, Qun He, Yu Fan, Jian-Hua Zhang, Yuan Jiang, Zhi-Song He, Hong -Zhen Li
Summary: In this case series, we discussed 4 t-NEPC cases who were treated with partial stereotactic ablative radiotherapy (P-SABR) for bulky tumors. The results indicated that P-SABR is safe and effective in the treatment of a large prostate mass and may prolong the survival of these patients.
TRANSLATIONAL ANDROLOGY AND UROLOGY
(2023)
Article
Oncology
Xiaojiang Duan, Lei Xia, Zhuochen Zhang, Yanan Ren, Martin G. Pomper, Steven P. Rowe, Xuesong Li, Nan Li, Ning Zhang, Hua Zhu, Zhi Yang, Xinan Sheng, Xing Yang
Summary: This study developed a bicyclic peptide-based radiotracer Ga-68-N188 for targeting Nectin-4 and conducted preclinical and translational studies. The results demonstrated that Ga-68-N188 has high affinity and specific uptake for Nectin-4, and can quantitatively image the expression level of Nectin-4 in different organs. The findings of this study provide a companion diagnostic tool for treatments targeting Nectin-4.
CLINICAL CANCER RESEARCH
(2023)
Article
Respiratory System
Chuan-cai Xu, Zhi-song He, Wei Lei, Jin-zhou Zhu, Da-guo Zhao, Jin-dan Kong, Yao Wei, Ying Xu, Jian-An Huang
Summary: This study found that patients with breakthrough infections after receiving the COVID-19 vaccine had higher lymphocyte counts, anti-SARS-CoV-2 spike IgG and IgM antibody titers within 60 days of receiving the second dose compared to those with a 60-day or longer interval. Additionally, the IL-6 level was significantly lower in the group with a shorter interval.
CLINICAL RESPIRATORY JOURNAL
(2023)
Article
Oncology
Li Zhou, Zhiting Shao, Yiqiang Liu, Xieqiao Yan, Juan Li, Xiaowen Wu, Bixia Tang, Siming Li, Chuanliang Cui, Zhihong Chi, Lu Si, Yan Kong, Lili Mao, Bin Lian, Xuan Wang, Xue Bai, Jie Dai, Jun Guo, Xinan Sheng
Summary: This study reports on the expression of HER2 in patients with urothelial carcinoma, analyzes its association with clinical characteristics and prognosis, and explores the efficacy of disitamab vedotin in a real-world setting. The results show that HER2 positivity is associated with survival in urothelial carcinoma patients and receiving disitamab vedotin treatment improves prognosis. This study suggests that the new-generation anti-HER2 ADC treatment has improved the survival of patients with urothelial carcinoma, and HER2 expression is no longer a poor prognostic factor.
Article
Cell & Tissue Engineering
Lvzhong Hu, Jinhua Zhou, Zhisong He, Lin Zhang, Fangzhou Du, Mengting Nie, Yao Zhou, Hang Hao, Lixing Zhang, Shuang Yu, Jingzhong Zhang, Youguo Chen
Summary: The study found that implanting human umbilical cord mesenchymal stem cells (hUC-MSCs) in a fibrin hydrogel scaffold can promote skin repair, prolong cell survival, and accelerate wound healing. The hydrogel scaffold provides a stable environment for cell adhesion, proliferation, and migration, while the combination therapy with hUC-MSCs promotes epithelial regeneration and angiogenesis. It exhibits a remarkable therapeutic effect, more effective than monotherapy with hUC-MSCs or hydrogel.
CELL TRANSPLANTATION
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Jun Wang, Pei Dong, Yuanyuan Qu, Wenhao Xu, Zhaohui Zhou, Kang Ning, Yulu Peng, Longbin Xiong, Zhen Li, Xiangpeng Zou, Zhenhua Liu, Mingzhao Li, Zhisong He, Junhang Luo, Xi Tian, Hailiang Zhang, Shengjie Guo, Hui Han, Fangjian Zhou, Shaohan Yin, Dingwei Ye, Chunping Yu, Zhiling Zhang
Summary: This study investigated the association between computed tomography-assessed body composition and survival outcomes in patients with metastatic renal cell carcinoma (mRCC) receiving immunotherapy. The results showed that high subcutaneous adipose tissue percentage (SAT%) predicts better survival outcomes and this association is consistent in different subgroups.
EUROPEAN RADIOLOGY
(2023)
Meeting Abstract
Oncology
Xinan Sheng, Li Zhou, Zhisong He, Hongqian Guo, Xieqiao Yan, Siming Li, Huayan Xu, Juan Li, Zhihong Chi, Lu Si, Chuanliang Cui, Lili Mao, Bin Lian, Bixia Tang, Xuan Wang, Xue Bai, Jun Guo
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Meeting Abstract
Oncology
Xinan Sheng, Zhisong He, Yanxia Shi, Hong Luo, Weiqing Han, Xin Yao, Benkang Shi, Jiyan Liu, Changlu Hu, Ziling Liu, Hongqian Guo, Guohua Yu, Zhigang Ji, Shiying Yu, Yi Hu, Jianming Guo, Jianming Ying, Jianmin Fang, Aiping Zhou, Jun Guo
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Meeting Abstract
Oncology
Zhisong He, Hailong Hu, Yuanjie Niu, Zhaoxia Guo, Feng Ding, Yunkai Wang, Wang Wang, Tao Zhou, Shanbo Cao, Feng Lou, Huina Wang
JOURNAL OF CLINICAL ONCOLOGY
(2022)